HIGHBuilt-in & outside partyPipeline
anito-cel
“10-K Item 1A: 'have only one product candidate in late-stage clinical development...anito-cel, there is no assurance that the safety measures'”
ACLX · Concentration risk · 10-K extracted
Arcellx (ACLX) concentration risks
Updated
The most significant concentration Arcellx discloses is anito-cel, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Arcellx’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH1
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMOutside partySupplier
Kite
“10-K Item 1A: 'We depend on Kite for certain development, manufacturing and commercialization activities with respect to certain of our product candidates'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24Arcellx's concentration profile is defined by two large disclosed dependencies: a single late-stage pipeline asset and a development, manufacturing, and commercialization partner. The company has only one product candidate in late-stage clinical development, anito-cel. By disclosed size this pipeline exposure is large, and its character is mixed — it reflects both the structural reality of a company at this stage of drug development and the idiosyncratic risk that a single clinical or regulatory outcome could substantially alter the investment thesis. Because anito-cel is the sole late-stage asset, there is no diversification within the pipeline to buffer against an adverse result. The dependency on Kite compounds the pipeline concentration: Arcellx relies on Kite for certain development, manufacturing, and commercialization activities with respect to certain of its product candidates. By disclosed size this is a moderate dependency, and its character is one of partnership reliance rather than pure supply-chain fragility. Kite's involvement means that key execution steps in anito-cel's development and potential commercialization are shared with an external party, and any deterioration in that relationship — whether operational, financial, or contractual — could affect timelines and cost structures in ways that Arcellx cannot fully control unilaterally. Taken together, the two exposures describe a company whose near-term value is concentrated in a single asset and a single key partner. There is no disclosed customer or geographic concentration to consider alongside these, because the company is not yet generating commercial revenue. The priorities for investors are the anito-cel clinical trajectory and the stability of the Kite partnership.
For the engine’s reasoning on ACLX’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ACLX● | Arcellx, Inc. | 1 | 1 | 0 | 2 |
| AGIO | Agios Pharmaceuticals, Inc. | 1 | 0 | 0 | 1 |
| ALMS | Alumis Inc. | 1 | 0 | 0 | 1 |
| ADMA | ADMA Biologics Inc | 0 | 1 | 0 | 1 |
| ALNY | Alnylam Pharmaceuticals, Inc. | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.